Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15830041 | 0.83 | PRMT5 (0.49) | PRMT5HCRTR1HCRTR2IKBKBNAMPT | |
| SCHEMBL17308301 | 0.83 | LOX (0.52) | HCRTR1HCRTR2LOXLOXL2LNPEP | |
| SCHEMBL20890609 | 0.82 | LOXL2 (0.60) | HCRTR1HCRTR2LOXLOXL2 | |
| SCHEMBL18149438 | 0.82 | IKBKB (0.52) | PRMT5HCRTR1HCRTR2IKBKBNAMPT | |
| SCHEMBL17572955 | 0.81 | PRMT5 (0.55) | PRMT5IKBKBNAMPTCYP4F2CYP4A11 | |
| SCHEMBL17308310 | 0.80 | CACNB4 (0.48) | HCRTR1HCRTR2LOXLOXL2 | |
| SCHEMBL19473347 | 0.80 | PRMT5 (0.49) | PRMT5IKBKBNAMPTCYP4F2CYP4A11 | |
| SCHEMBL16217383 | 0.80 | PRMT5 (0.47) | PRMT5HCRTR1HCRTR2IKBKBNAMPT | |
| SCHEMBL17308336 | 0.80 | LOX (0.66) | HCRTR1HCRTR2LOXLOXL2 | |
| SCHEMBL21566655 | 0.79 | GPR119 (0.44) | PRMT5IKBKBNAMPTCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885HCRTR1 4573/4885HCRTR2 4488/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885HCRTR1 1276/4885HCRTR2 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.